Metabolic-Associated Fatty Liver Disease and Sarcopenia

• Triada Bali ^[1] ; Lampros Chrysavgis ^[1] ; Evangelos Cholongitas ^[1]
  1. [1] National and Kapodistrian University of Athens

     National and Kapodistrian University of Athens

     Dimos Athens, Grecia

     
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 52, Nº. 3, 2023, págs. 497-508
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • The current evidence indicates a strong association between sarcopenia, the loss of muscle mass and strength, and metabolic-associated fatty liver disease (MAFLD). The two entities share many common pathophysiologic mechanisms, and their coexistence may result in higher rates of morbidity and mortality. Therefore, given their increasing incidence in the modern world, there is a need for a better understanding of the liver-muscle axis for early identification of sarcopenia in patients with MAFLD and vice versa. This review aims at presenting current data regarding the correlation between sarcopenia and MAFLD, the associated comorbidities, and the need for effective therapies.